Current Cancer Drug Targets

Papers
(The H4-Index of Current Cancer Drug Targets is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
LMNB1/CDKN1A Signaling Regulates the Cell Cycle and Promotes Hepatocellular Carcinoma Progression97
Identification of ATM Mutation as a Potential Prognostic Biomarker for Immune Checkpoint Inhibitors Therapy43
Immune Checkpoint Inhibitors for Advanced Biliary Tract Cancer39
Development of Chromatin Regulator-related Molecular Subtypes and a Signature to Predict Prognosis and Immunotherapeutic Response in Head and Neck Squamous Cell Carcinoma37
FHOD3 Promotes the Progression of Lung Cancer by Regulating the Caspase-3-Mediated Signaling Pathway33
Expression, Prognostic Value, and Immune Infiltration of MTHFD Family in Bladder Cancer32
Knockdown of PRKD2 Enhances Chemotherapy Sensitivity in Cervical Cancer via the TP53/CDKN1A Pathway32
Artesunate overcomes lenvatinib resistance by inhibiting the STAT3/SLC25A27 pathway and promoting ferroptosis in hepatocellular carcinoma29
Etiology-based Molecular Characterization of Hepatocellular Carcinoma Reveals SQLE's Contribution to Immunosuppressive Microenvironment27
A Review on Patient-derived 3D Micro Cancer Approach for Drug Screen in Personalized Cancer Medicine21
Silencing HEATR1 Rescues Cisplatin Resistance of Non-small Cell Lung Cancer by Inducing Ferroptosis via the p53/SAT1/ALOX15 Axis19
MiR-124-3p Suppresses Glioma Cells Progression by Targeting STAT3/NAMPT and Inhibiting AKT/ERK Signaling19
Bioinformatics and Experimental Study Revealed LINC00982/ miR-183-5p/ABCA8 Axis Suppresses LUAD Progression19
DDX18 as a Prognostic Biomarker Associated with Pan-Cancer Immune Infiltration and Drug Sensitivity17
Micro-fragmented Fat Inhibits the Progression of Human Mesothelioma Xenografts in Mice17
Efficacy and Safety of Immunotherapy Combined with Anlotinib as First-Line Treatment in Older NSCLC Patients with PD-L1 Expression<50%17
Combined RNAi of CTTN and FGF2 Modulates Cell Migration, Invasion and G1/S Transition of Hepatocellular Carcinoma through Ras/ERK Signaling Pathway17
Progress in Metabolic Studies of Gastric Cancer and Therapeutic Implications17
0.068169116973877